Literature DB >> 10468060

Prescribing during pregnancy and lactation with reference to the Swedish classification system. A population-based study among Danish women.

C Olesen1, H T Sørensen, L de Jong-van den Berg, J Olsen, F H Steffensen.   

Abstract

AIM: To assess the current prescribing pattern for 15,756 primiparae before, during, and after their pregnancies with reference to fetal and neonatal risk.
METHOD: A prescription database study with linkage to The Danish Medical Birth Registry from 1991 to 1996. The drug subsidy system in Danish retail pharmacies, made it possible to identify prescriptions by individual use. All 34,334 prescriptions were set against the Swedish classification of risk of drug use in pregnancy and lactation.
RESULTS: During pregnancy, safe (group A), potentially harmful (group B3, C, and D), and non-classifiable drugs accounted for 40.9%, 26.6% and 28.7% respectively. The proportion of women who redeemed drugs was 29.2%, 8.6%, 18.7% and 0.9% from drug groups A, B, C and D respectively. The proportion of prescriptions from high risk groups declined during the course of pregnancy. Postpartum, safe drugs (group I and II), drugs with possible harmful neonatal effects (group III), and non-classifiable drugs accounted for 43.5%, 4.8%, and 35.8% of the prescriptions, respectively.
CONCLUSION: According to the Swedish classification system, we found that during pregnancy and lactation a high proportion of Danish women were exposed to one or more drugs in high risk groups; furthermore, knowledge regarding their safety for the fetus and neonate was limited for a large proportion of the prescriptions. Current evidence about long-term effects of prenatal exposure stresses the need for long-term follow-up of health and development among exposed children.

Entities:  

Mesh:

Year:  1999        PMID: 10468060     DOI: 10.1034/j.1600-0412.1999.780805.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  19 in total

1.  Drugs dispensed in primary care during pregnancy: a record-linkage analysis in Tayside, Scotland.

Authors:  Linda Irvine; Robert W V Flynn; Gillian Libby; Iain K Crombie; Josie M M Evans
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

2.  Prevalence and patterns of antidepressant drug use during pregnancy.

Authors:  Tessa Ververs; Hans Kaasenbrood; Gerard Visser; Fred Schobben; Lolkje de Jong-van den Berg; Toine Egberts
Journal:  Eur J Clin Pharmacol       Date:  2006-08-08       Impact factor: 2.953

3.  Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during, and after pregnancy: a population-based cohort study.

Authors:  Marte Handal; Anders Engeland; Marit Rønning; Svetlana Skurtveit; Kari Furu
Journal:  Eur J Clin Pharmacol       Date:  2011-04-12       Impact factor: 2.953

4.  Medicines prescribed for asthma, discontinuation and perinatal outcomes, including breastfeeding: A population cohort analysis.

Authors:  Gareth Davies; Sue Jordan; Daniel Thayer; David Tucker; Ioan Humphreys
Journal:  PLoS One       Date:  2020-12-09       Impact factor: 3.240

5.  Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection.

Authors:  Linda de Jonge; Priscilla A Zetstra-van der Woude; H Jens Bos; Lolkje T W de Jong-van den Berg; Marian K Bakker
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

6.  Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19,874 Danish women.

Authors:  Charlotte Olesen; Nana Thrane; Tine Brink Henriksen; Vera Ehrenstein; Jørn Olsen
Journal:  Eur J Clin Pharmacol       Date:  2006-05-04       Impact factor: 2.953

7.  Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs.

Authors:  Kathleen Uhl; Dianne L Kennedy; Sandra L Kweder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  Medical databases in studies of drug teratogenicity: methodological issues.

Authors:  Vera Ehrenstein; Henrik T Sørensen; Leiv S Bakketeig; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

9.  Randomized trial to improve prescribing safety during pregnancy.

Authors:  Marsha A Raebel; Nikki M Carroll; Julia A Kelleher; Elizabeth A Chester; Sally Berga; David J Magid
Journal:  J Am Med Inform Assoc       Date:  2007-04-25       Impact factor: 4.497

10.  Prescription of hazardous drugs during pregnancy.

Authors:  Heli Malm; Jaana Martikainen; Timo Klaukka; Pertti J Neuvonen
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.